JP2989002B2
(ja)
*
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
DK1090645T3
(da)
*
|
1994-02-08 |
2006-03-27 |
Amgen Inc |
Oral tilförsel af kemisk modificerede proteiner
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
CA2204726A1
(fr)
*
|
1994-11-09 |
1996-12-27 |
Robin E. Offord |
Polymeres fonctionnalises destines a une ligation dirigee
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
DK0858343T3
(da)
|
1995-11-02 |
2004-05-10 |
Schering Corp |
Kontinuerlig lavdosis cytokininfusionsterapi
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
AU736876B2
(en)
|
1996-12-06 |
2001-08-02 |
Amgen, Inc. |
Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
|
ATE200030T1
(de)
*
|
1997-01-29 |
2001-04-15 |
Polymasc Pharmaceuticals Plc |
Pegylationsverfahren
|
DE69841682D1
(de)
|
1997-06-06 |
2010-07-08 |
Kyowa Hakko Kirin Co Ltd |
Chemisch modifizierte polypeptide
|
WO1999003887A1
(fr)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derives d'hormone de croissance et proteines associees
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
SK286654B6
(sk)
|
1998-04-28 |
2009-03-05 |
Laboratoires Serono Sa |
Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom
|
EP1213029A1
(fr)
*
|
1998-05-15 |
2002-06-12 |
Schering Corporation |
Thérapie combinatoire contenant de la ribavirine et de l'interferon alpha chez les patients ayant une infection chronique d'hépatite C et n'ayant pas été traités par un agent antiviral
|
NL1009601C2
(nl)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
|
JP2002520040A
(ja)
*
|
1998-07-16 |
2002-07-09 |
ハイセック,インコーポレーテッド |
新規cd39様ポリペプチドに関する方法および材料
|
CA2728907C
(fr)
|
1998-08-06 |
2015-11-24 |
Mountain View Pharmaceuticals, Inc. |
Conjugues peg - urate oxydase et utilisation associee
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
EP2599503B1
(fr)
|
1998-10-16 |
2017-05-17 |
Biogen MA Inc. |
Conjugués de polymère d'interféron bêta-1A et leurs utilisations
|
PT1121382E
(pt)
*
|
1998-10-16 |
2006-10-31 |
Biogen Idec Inc |
Proteinas de fusao do interferao beta e as respectivas utilizacoes
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
PL219605B1
(pl)
|
1998-10-23 |
2015-06-30 |
Kirin Amgen Inc |
Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
|
CA2352538A1
(fr)
*
|
1998-11-30 |
2000-06-08 |
Eli Lilly And Company |
Composes erythropoietiques
|
ATE526401T1
(de)
|
1999-01-14 |
2011-10-15 |
Bolder Biotechnology Inc |
Verfahren zur herstellung von proteinen mit freien cysteinresten
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
SI1157037T1
(en)
*
|
1999-01-29 |
2003-12-31 |
F. Hoffmann-La Roche Ag |
Gcsf conjugates
|
IL144361A0
(en)
*
|
1999-01-29 |
2002-05-23 |
Hoffmann La Roche |
Gcsf conjugates
|
WO2000051626A1
(fr)
*
|
1999-03-01 |
2000-09-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Preparations de g-csf modifiees chimiquement
|
US6485718B1
(en)
*
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7160924B2
(en)
*
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US7074878B1
(en)
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
BR0107561A
(pt)
|
2000-01-10 |
2002-11-19 |
Maxygen Holdings Ltd |
Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
EP1982732A3
(fr)
|
2000-02-11 |
2011-06-08 |
Bayer HealthCare LLC |
Conjugués de type facteur VII ou VIIA
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
ES2220673T3
(es)
|
2000-02-29 |
2004-12-16 |
Pfizer Products Inc. |
Factor estimulante de colonias de granulocitos estabilizado.
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
AU2001289307A1
(en)
*
|
2000-04-06 |
2001-10-23 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
AU2001257032A1
(en)
*
|
2000-04-14 |
2001-10-30 |
University Of South Carolina Research Foundation |
Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
|
DK1290013T3
(da)
|
2000-04-21 |
2006-06-26 |
Amgen Inc |
Apo-A1/All-peptidderivater
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
JP2004502783A
(ja)
*
|
2000-07-12 |
2004-01-29 |
グリフォン セラピューティクス,インコーポレーテッド |
ケモカイン受容体モジュレーター、その産生および利用方法
|
JP2004508338A
(ja)
*
|
2000-09-08 |
2004-03-18 |
グリフォン セラピューティクス,インコーポレーテッド |
ポリマー修飾合成タンパク質
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
WO2002026265A2
(fr)
*
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Interleukine 10 pegylee
|
DE60137525D1
(de)
*
|
2000-10-16 |
2009-03-12 |
Chugai Pharmaceutical Co Ltd |
Peg-modifiziertes erythropoietin
|
ATE537845T1
(de)
*
|
2000-10-31 |
2012-01-15 |
Pr Pharmaceuticals Inc |
Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
|
WO2002036626A1
(fr)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
Polypeptides multimeres comportant une seule chaine
|
CN1321134C
(zh)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
一种生物活性蛋白质的非均一制品及其制备方法
|
CA2431800C
(fr)
*
|
2000-12-14 |
2014-07-08 |
Amylin Pharmaceuticals, Inc. |
Peptide yy et antagonistes de peptides yy destines au traitement des troubles du metabolisme
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
ES2361824T3
(es)
|
2000-12-20 |
2011-06-22 |
F. Hoffmann-La Roche Ag |
Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
KR20030074785A
(ko)
*
|
2001-02-06 |
2003-09-19 |
메르크 파텐트 게엠베하 |
감소된 면역원성을 갖는 개질 과립구 집락 자극인자(g-csf)
|
EP1234583A1
(fr)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
Conjugués du PEG et du HGF-NK4
|
IL156059A0
(en)
|
2001-02-27 |
2003-12-23 |
Maxygen Aps |
NEW INTERFERON beta-LIKE MOLECULES
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
EP1383480A4
(fr)
*
|
2001-04-30 |
2006-05-24 |
Targeted Genetics Corp |
Complexes d'administration de medicaments contenant des lipides et leurs methodes de production
|
CN100448891C
(zh)
|
2001-05-11 |
2009-01-07 |
安姆根有限公司 |
与tall-1结合的肽和相关分子
|
EP1421175B1
(fr)
*
|
2001-06-28 |
2008-11-19 |
Mountain View Pharmaceuticals, Inc. |
Proteinases a stabilisation polymerique
|
JP4444652B2
(ja)
|
2001-07-11 |
2010-03-31 |
マキシゲン・ホールディングズ・リミテッド |
G−csf結合体
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
CN1738635A
(zh)
*
|
2001-10-05 |
2006-02-22 |
印特缪恩股份有限公司 |
用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
US6908963B2
(en)
*
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7056500B2
(en)
|
2001-10-18 |
2006-06-06 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of opioid antagonists
|
US20040265971A1
(en)
*
|
2001-11-19 |
2004-12-30 |
Hidetaka Sato |
Drug mobilizing pluripotent stem cells from tissue into peripheral blood
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
MXPA04004809A
(es)
*
|
2001-11-20 |
2004-08-11 |
Pharmacia Corp |
Conjugados de hormona de crecimiento humana modificada quimicamente.
|
KR100480432B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
G-csf와 폴리에틸렌글리콜 유도체의 배합체
|
AU2002346686A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
WO2003059988A2
(fr)
|
2002-01-14 |
2003-07-24 |
The General Hospital Corporation |
Polymeres de polycetal biodegradables et procedes de preparation et d'utilisation associes
|
RS55578B1
(sr)
*
|
2002-01-18 |
2017-06-30 |
Biogen Ma Inc |
Polimerna jedinjenja polialkilena i njihova upotreba
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
US20060122106A1
(en)
*
|
2002-06-14 |
2006-06-08 |
Amylin Pharmaceuticals, Inc |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
CA2492803C
(fr)
*
|
2002-07-19 |
2013-11-05 |
The General Hospital Corporation |
Conjugats d'oximes, procedes de synthese de ces produits et leurs usages
|
MXPA05002219A
(es)
|
2002-08-28 |
2005-07-05 |
Immunex Corp |
Composiciones y metodos para tratar una enfermedad cardiovascular.
|
BR0314172A
(pt)
|
2002-09-09 |
2005-07-26 |
Nektar Therapeutics Al Corp |
Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
PL396711A1
(pl)
*
|
2002-12-26 |
2011-12-19 |
Mountain View Pharmaceuticals, Inc. |
Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
|
BR0317742A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de interferon-beta com potência biológica aumentada
|
AU2003292696A1
(en)
|
2002-12-26 |
2004-08-10 |
Takeda Pharmaceutical Company Limited |
Metastin derivative and use thereof
|
AU2003303595A1
(en)
|
2002-12-30 |
2004-07-29 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
CN1997666A
(zh)
*
|
2003-02-26 |
2007-07-11 |
印特缪恩股份有限公司 |
聚乙二醇修饰的干扰素组合物及其使用方法
|
WO2004078127A2
(fr)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Methode d'administration continue pour traiter les infections provoquees par le virus de l'hepatite
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
DK2177620T3
(en)
|
2003-03-05 |
2015-01-26 |
Halozyme Inc |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, use and pharmaceutical compositions comprising thereof
|
US7803777B2
(en)
|
2003-03-14 |
2010-09-28 |
Biogenerix Ag |
Branched water-soluble polymers and their conjugates
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
CA2530725A1
(fr)
*
|
2003-03-28 |
2004-10-07 |
Biopolymed Inc. |
Materiau biologiquement actif conjugue avec un polymere biocompatible avec un complexe 1:1, technique de preparation de celui-ci et composition pharmaceutique comprenant celui-ci
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
CA2520875A1
(fr)
|
2003-03-31 |
2004-10-21 |
Xencor, Inc. |
Procedes de pegylation rationnelle de proteines
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
JP4674702B2
(ja)
|
2003-04-09 |
2011-04-20 |
バイオジェネリクス エージー |
グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド
|
DK2599502T3
(en)
*
|
2003-04-11 |
2017-04-18 |
Antriabio Inc |
Process for Preparation of Site-Specific Protein Conjugates
|
ATE459647T1
(de)
|
2003-04-15 |
2010-03-15 |
Glaxosmithkline Llc |
Humane il-18 substitutionsmutanten und deren konjugate
|
CA2864810A1
(fr)
|
2003-04-18 |
2004-11-04 |
Biogen Idec Ma, Inc. |
Neublastine a conjugaison polymere glycosylee
|
WO2005016241A2
(fr)
|
2003-05-16 |
2005-02-24 |
Intermune, Inc. |
Ligands des recepteurs des chimiokines synthetiques et leurs methodes d'utilisation
|
SI1656410T1
(sl)
*
|
2003-07-22 |
2010-07-30 |
Nektar Therapeutics |
Postopek za pripravo funkcionaliziranih polimerov iz polimer alkoholov
|
WO2005012484A2
(fr)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Conjugues anticorps-toxines
|
EP1648935A2
(fr)
|
2003-07-25 |
2006-04-26 |
Amgen Inc. |
Antagonistes et agonistes de ldcam et procedes d'utilisation
|
WO2005014655A2
(fr)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugues d'amidon d'hydroxyalkyle et de proteine
|
PL1666496T3
(pl)
|
2003-08-25 |
2014-08-29 |
Toray Industries |
Kompozyt interferonu beta
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
HUE036290T2
(hu)
|
2003-09-17 |
2018-06-28 |
Nektar Therapeutics |
Többkarú polimer vegyületek
|
CA2536182C
(fr)
*
|
2003-09-22 |
2012-07-24 |
Boehringer Ingelheim International Gmbh |
Peptides macrocycliques actifs contre le virus de l'hepatite c
|
JP4890253B2
(ja)
*
|
2003-10-09 |
2012-03-07 |
アンブレツクス・インコーポレイテツド |
アジドまたはアセチレン末端水溶性ポリマー
|
CN1867581B
(zh)
|
2003-10-10 |
2012-02-01 |
诺沃挪第克公司 |
Il-21衍生物
|
AU2004279895A1
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc |
Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
|
WO2005037214A2
(fr)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
WO2005040758A2
(fr)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Utilisation de pirfenidone dans des posologies therapeutiques
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
WO2005044836A2
(fr)
|
2003-11-05 |
2005-05-19 |
Genovoxx Gmbh |
Composes nucleotidiques macromoleculaires et leurs procedes d'utilisation
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
WO2005053730A1
(fr)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
Agent therapeutique contre l'insuffisance cardiaque terminale
|
WO2005067963A1
(fr)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Utilisation d'un interferon modifie par du polyethylene glycol dans des schemas posologiques de dosage therapeutique
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
CA2552892C
(fr)
|
2004-01-08 |
2014-08-05 |
Neose Technologies, Inc. |
Glycosylation de peptides liee a o
|
EP1730167B1
(fr)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Peptides macrocycliques actifs contre le virus de l'hepatite c
|
US8778880B2
(en)
|
2004-02-02 |
2014-07-15 |
Ambrx, Inc. |
Human growth hormone modified at position 35
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
JP5638177B2
(ja)
*
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
CN102174115B
(zh)
|
2004-02-11 |
2014-05-14 |
安米林药品有限责任公司 |
具有可选择特性的杂合多肽
|
WO2005084303A2
(fr)
*
|
2004-03-01 |
2005-09-15 |
Enzon Pharmaceuticals, Inc. |
Conjugues polymeres de l'interferon beta
|
EP1744786A2
(fr)
*
|
2004-03-23 |
2007-01-24 |
Amgen Inc. |
Compositions de proteines chimiquement modifiees et procedes
|
WO2005115477A2
(fr)
*
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques
|
EP1586334A1
(fr)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugés avec PEG
|
RU2006145020A
(ru)
|
2004-05-19 |
2008-06-27 |
Максиджен, Инк. (Us) |
Полипептиды и конъюгаты интерферона-альфа
|
WO2005123113A2
(fr)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Compositions d'interferons et leurs methodes d'utilisation
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
EP2113513B1
(fr)
|
2004-06-25 |
2016-05-18 |
Takeda Pharmaceutical Company Limited |
Dérivés de métastine et utilisation associée
|
WO2006004959A2
(fr)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Peg-interferon alpha-1b
|
EP1773400A2
(fr)
*
|
2004-07-08 |
2007-04-18 |
Amgen Inc. |
Peptides therapeutiques
|
EP1771066A2
(fr)
*
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1786454B1
(fr)
|
2004-08-19 |
2010-07-21 |
Biogen Idec MA Inc. |
Variants de neublastine
|
EP1784203B1
(fr)
|
2004-08-19 |
2010-06-30 |
Biogen Idec MA Inc. |
Repliement des proteines de la famille du facteur de croissance transformant beta
|
EP1799249A2
(fr)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Interferon alpha glycopegyle
|
US20060204512A1
(en)
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
HUE026826T2
(en)
|
2004-10-29 |
2016-07-28 |
Ratiopharm Gmbh |
Modeling and glycopegylation of fibroblast growth factor (FGF)
|
WO2006055260A2
(fr)
|
2004-11-05 |
2006-05-26 |
Northwestern University |
Utilisation de scf et de scf dans le traitement de l'ischemie cerebrale et des troubles neurologiques
|
EP3000826A1
(fr)
|
2004-12-13 |
2016-03-30 |
Amylin Pharmaceuticals, LLC |
Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes
|
BRPI0516385B1
(pt)
|
2004-12-22 |
2021-07-20 |
Ambrx, Inc. |
Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo
|
WO2006073846A2
(fr)
*
|
2004-12-22 |
2006-07-13 |
Ambrx, Inc. |
Procedes pour l'expression et la purification d'hormone de croissance humaine recombinante
|
NZ584597A
(en)
|
2004-12-22 |
2011-09-30 |
Ambrx Inc |
Modified human growth hormone
|
EP1674113A1
(fr)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Conjugués de l'IGF-1 et du poly(éthylène glycol)
|
AU2005319518B2
(en)
*
|
2004-12-22 |
2010-09-09 |
Ambrx, Inc. |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
CN103520735B
(zh)
|
2004-12-22 |
2015-11-25 |
Ambrx公司 |
包含非天然编码的氨基酸的人生长激素配方
|
JP4951527B2
(ja)
|
2005-01-10 |
2012-06-13 |
バイオジェネリックス アーゲー |
糖peg化顆粒球コロニー刺激因子
|
CN103172747A
(zh)
|
2005-01-25 |
2013-06-26 |
细胞治疗学公司 |
体内半衰期改变的生物活性蛋白质偶联物
|
AU2005326226B2
(en)
*
|
2005-01-31 |
2010-11-11 |
Eci, Inc. |
Immunopotentiating agent
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
SG159551A1
(en)
*
|
2005-02-11 |
2010-03-30 |
Amylin Pharmaceuticals Inc |
Gip analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
*
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2006094530A1
(fr)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Conjugues de proteines et de dipolymeres et leurs procedes de preparation
|
WO2007010552A2
(fr)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
Conjugue d'erythropoietine peg n-terminal
|
EP1888094B1
(fr)
|
2005-03-31 |
2009-08-12 |
Amylin Pharmaceuticals, Inc. |
Amyline et agonistes d'amyline utiles dans le traitement des maladies et troubles psychiatriques
|
EP1868652A2
(fr)
|
2005-04-05 |
2007-12-26 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
LT3321359T
(lt)
|
2005-04-11 |
2021-05-10 |
Horizon Pharma Rheumatology Llc |
Urato oksidazės variantinės formos ir jų panaudojimas
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2007044083A2
(fr)
|
2005-05-18 |
2007-04-19 |
Maxygen, Inc. |
Polypeptides d'interferon-alpha mis au point genetiquement
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
JP2008545754A
(ja)
*
|
2005-06-01 |
2008-12-18 |
アルザ・コーポレーシヨン |
ポリエチレングリコール試薬をアシル化するためのバイオコンジュゲーション反応
|
EP1888119B1
(fr)
*
|
2005-06-01 |
2011-03-09 |
Maxygen, Inc. |
Polypeptides g-csf pegyles et procedes de production correspondants
|
WO2007009208A1
(fr)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Gm-csf humain modifie au poly(ethylene glycol) qui presente une activite biologique accrue
|
MX2007015058A
(es)
*
|
2005-06-03 |
2008-01-28 |
Ambrx Inc |
Moleculas de interferon humano mejoradas y sus usos.
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
MX2007015819A
(es)
*
|
2005-06-13 |
2008-02-22 |
Nastech Pharm Co |
Suministro de derivados peptidicos a traves de la mucosa.
|
ATE524183T1
(de)
|
2005-06-17 |
2011-09-15 |
Novartis Ag |
Verwendung von sanglifehrin bei der hcv-therapie
|
JP5335422B2
(ja)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
|
TW200722104A
(en)
*
|
2005-06-20 |
2007-06-16 |
Pepgen Corp |
Low-toxicity, long-circulating human interferon-α analogs
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
EP2412744B1
(fr)
|
2005-07-18 |
2014-01-22 |
Nektar Therapeutics |
Procédé pour préparer des polymères fonctionnalisés ramifiés au moyen de noyaux de polyol ramifiés
|
KR100735784B1
(ko)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
WO2007015591A1
(fr)
*
|
2005-08-02 |
2007-02-08 |
Cheil Industries Inc. |
Composition de résine époxy pour emballer un dispositif semi-conducteur
|
AU2006278490A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics |
Conjugates of a G-CSF moiety and a polymer
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
EP1922336B1
(fr)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Polypeptides hybrides presentant des proprietes selectionnables
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
DK1937824T3
(da)
|
2005-08-18 |
2013-04-02 |
Ambrx Inc |
Sammensætninger af tRNA og anvendelser deraf
|
PL2347762T3
(pl)
|
2005-08-19 |
2019-09-30 |
Amylin Pharmaceuticals, Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
WO2007047303A2
(fr)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Polypeptides glutenase peg
|
NZ597082A
(en)
|
2005-10-13 |
2013-11-29 |
Human Genome Sciences Inc |
Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
AU2006304856A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Synageva Biopharma Corp. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
WO2007056191A2
(fr)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Purification de sucre de nucleotide en utilisant des membranes
|
WO2007056448A2
(fr)
*
|
2005-11-08 |
2007-05-18 |
Ambrx, Inc. |
Accelerateurs destines a la modification d’acides amines non-naturels et de polypeptides formes d'acides amines non-naturels
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
ES2547554T3
(es)
*
|
2005-11-16 |
2015-10-07 |
Ambrx, Inc. |
Métodos y composiciones que comprenden aminoácidos no naturales
|
ES2529065T3
(es)
*
|
2005-12-14 |
2015-02-16 |
Ambrx, Inc. |
Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
EP2918283B1
(fr)
|
2005-12-30 |
2018-01-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Libération prolongée de la neuréguline destinée à améliorer la fonction cardiaque
|
AU2007205545B9
(en)
|
2006-01-12 |
2012-10-18 |
Hokusan Co. Ltd. |
Oral composition containing interferon-alpha
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
EP1991577A2
(fr)
|
2006-01-31 |
2008-11-19 |
Parkinson, John F. |
Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
|
EP2319542B1
(fr)
|
2006-02-21 |
2018-03-21 |
Nektar Therapeutics |
Polymères dégradables segmentés et conjugués obtenus à partir de ceux-ci
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
EP2010569A4
(fr)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Anticorps humains spécifiques à des matières et des procédés à base de gastrines
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
MX2008013119A
(es)
|
2006-04-11 |
2008-10-21 |
Novartis Ag |
Inhibidores de hcv/vih y sus usos.
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
EP2029160A2
(fr)
*
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Procédés permettant de rétablir l'équilibre glycémique
|
JP5406710B2
(ja)
|
2006-05-19 |
2014-02-05 |
グライコフィ, インコーポレイテッド |
エリスロポエチン組成物
|
EP2029738A2
(fr)
|
2006-05-24 |
2009-03-04 |
Novo Nordisk Health Care AG |
Analogues de facteur ix ayant une demi-vie prolongée in vivo
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
WO2007149594A2
(fr)
|
2006-06-23 |
2007-12-27 |
Quintessence Biosciences, Inc. |
Ribonucléases modifiées
|
CA2787343C
(fr)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprenant de la lcat modifiee et leur utilisation
|
JP2009543868A
(ja)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
癌治療に関する方法および組成物
|
CN101516388B
(zh)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
EP3299033A1
(fr)
*
|
2006-07-25 |
2018-03-28 |
Lipoxen Technologies Limited |
Polysialylation n-terminale
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
PL2054074T3
(pl)
*
|
2006-08-04 |
2015-03-31 |
Prolong Pharmaceuticals Llc |
Zmodyfikowana erytropoetyna
|
ITMI20061624A1
(it)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CN101484469B
(zh)
*
|
2006-08-31 |
2012-12-12 |
弗·哈夫曼-拉罗切有限公司 |
生产胰岛素样生长因子-ⅰ的方法
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
EP2069396B1
(fr)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
|
US8420792B2
(en)
*
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
PT2061878E
(pt)
*
|
2006-09-08 |
2014-04-22 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
JP5105554B2
(ja)
|
2006-09-28 |
2012-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
癌を処置するためのペグ化il−10の使用
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
MX2009003470A
(es)
*
|
2006-10-04 |
2009-04-14 |
Novo Nordisk As |
Azucares y glicopeptidos pegilados enlazados a glicerol.
|
WO2008051383A2
(fr)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Utilisation de co-solvants d'alcool pour améliorer les rendements de réaction de pegylation
|
TWI404726B
(zh)
|
2006-10-25 |
2013-08-11 |
Takeda Pharmaceutical |
腫瘤轉移抑制素衍生物及其用途
|
TW200833840A
(en)
|
2006-10-25 |
2008-08-16 |
Amgen Inc |
Toxin peptide therapeutic agents
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
EP2727936B1
(fr)
|
2006-11-22 |
2016-09-07 |
Bristol-Myers Squibb Company |
Agents thérapeutiques ciblés sur la base des protéines modifiées de récepteurs de tyrosine kinases, dont le IGF-IR
|
MX2009006082A
(es)
|
2006-12-08 |
2009-08-18 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
CN101245109B
(zh)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
|
AU2008232937B2
(en)
|
2007-03-30 |
2012-09-27 |
Ambrx, Inc. |
Modified FGF-21 polypeptides and their uses
|
ES2406267T3
(es)
|
2007-04-03 |
2013-06-06 |
Biogenerix Ag |
Métodos de tratamiento usando G-CSF glicopegilado
|
JP2008266219A
(ja)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
リジン及びシステイン残基を含まないタンパク質
|
EP2142205B1
(fr)
|
2007-05-01 |
2014-04-02 |
Biogen Idec MA Inc. |
Peptides de Neublastin pour augmenter la vascularisation dans les tissus avec de la perfusion réduite
|
EP2076533B1
(fr)
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Polypeptides d'interferon beta modifies et leurs utilisations
|
EP2738257A1
(fr)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Compositions et procédés pour produire des protéines de fusion bioactives
|
EP2162535A4
(fr)
*
|
2007-06-04 |
2011-02-23 |
Novo Nordisk As |
Glycosylation à liaisons o utilisant des n-acétylglucosaminyl transférases
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
US20110159523A1
(en)
*
|
2007-06-27 |
2011-06-30 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
US8168416B2
(en)
|
2007-07-26 |
2012-05-01 |
Amgen Inc. |
Modified lecithin-cholesterol acyltransferase enzymes
|
CN101352573B
(zh)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
|
US20090324609A1
(en)
|
2007-08-09 |
2009-12-31 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
UA98001C2
(uk)
|
2007-08-27 |
2012-04-10 |
Биодженерикс Аг |
Рідка лікарська форма кон'югата полімер-g-csf
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
WO2009046015A2
(fr)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Thérapies combinées pour traitement de diabète du type 1
|
JP2010540681A
(ja)
*
|
2007-10-08 |
2010-12-24 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
リボヌクレアーゼに基づく治療のための組成物及び方法
|
CA2702945C
(fr)
|
2007-10-23 |
2016-08-23 |
Nektar Therapeutics Al, Corporation |
Polymeres a bras multiples ciblant l'hydroxyapatite et conjugues prepares a partir de ces polymeres
|
JP5547083B2
(ja)
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
US20110124841A1
(en)
*
|
2007-12-13 |
2011-05-26 |
Monthony James F |
Polypeptides Modified by Protein Trans-Splicing Technology
|
DK2416157T3
(da)
|
2007-12-27 |
2014-08-18 |
Baxter Int |
Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler
|
US20100286067A1
(en)
*
|
2008-01-08 |
2010-11-11 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
WO2009120396A2
(fr)
*
|
2008-01-08 |
2009-10-01 |
The University Of California |
Compositions et procédés permettant de réguler l’expression de l’érythropoïétine, d’améliorer une anémie et de stimuler l’érythropoïèse
|
FI3219795T3
(fi)
|
2008-01-18 |
2024-06-12 |
Biomarin Pharmaceutical Inc |
Aktiivisten, erittäin fosforyloitujen, ihmisen lysosomaalisten sulfataasientsyymien valmistus ja niiden käyttötarkoitukset
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
WO2009103199A1
(fr)
|
2008-02-18 |
2009-08-27 |
江苏恒瑞医药股份有限公司 |
Conjugué de g-csf modifié par un polymère hydrosoluble
|
AU2009219232B2
(en)
|
2008-02-27 |
2014-02-27 |
Novo Nordisk A/S |
Conjugated Factor VIII molecules
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
CN101965516A
(zh)
*
|
2008-04-03 |
2011-02-02 |
弗·哈夫曼-拉罗切有限公司 |
聚乙二醇化胰岛素样生长因子测定
|
CA2720306C
(fr)
|
2008-04-03 |
2016-03-15 |
Biosteed Gene Expression Tech. Co., Ltd. |
Hormone de croissance modifiee par polyethyleneglycol double brin, son procede de preparation et son application
|
SG187427A1
(en)
|
2008-04-14 |
2013-02-28 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
EP2303313B1
(fr)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendines pour diminuer le cholestérol et les triglycérides
|
WO2009142773A2
(fr)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Protéines à domaines d’échafaudage à base de fibronectine multivalente
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
NZ600382A
(en)
*
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
EP2314609B1
(fr)
*
|
2008-07-30 |
2016-11-30 |
Takeda Pharmaceutical Company Limited |
Dérivé de métastine et son utilisation
|
EP2313457B1
(fr)
*
|
2008-07-31 |
2020-01-15 |
PharmaEssentia Corp. |
Conjugués peptide-polymère
|
KR101671537B1
(ko)
|
2008-08-11 |
2016-11-01 |
넥타르 테라퓨틱스 |
다분지형 중합체 알카노에이트 컨쥬게이트
|
WO2010030366A2
(fr)
|
2008-09-11 |
2010-03-18 |
Nektar Therapeutics |
Réactifs polymères alpha-hydroxy aldéhydiques et cétoniques et procédé de conjugaison
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
AU2009296397B2
(en)
|
2008-09-26 |
2012-11-08 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
CN102227443B
(zh)
|
2008-10-01 |
2014-05-14 |
昆特森斯生物科学公司 |
治疗性核糖核酸酶
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
ES2441941T3
(es)
|
2008-10-15 |
2014-02-07 |
Baxter Healthcare Sa |
Pegilación de factores de coagulación sanguínea recombinantes en presencia de anticuerpos enlazados
|
EP2349342B1
(fr)
*
|
2008-10-17 |
2018-06-27 |
Baxalta GmbH |
Facteurs sanguins modifiés renfermant un faible degré de polymère soluble dans l'eau
|
EP2337794B1
(fr)
*
|
2008-10-20 |
2013-07-31 |
USV Limited |
Procédé amélioré de pegylation de protéines
|
CA2740904C
(fr)
|
2008-10-21 |
2019-01-15 |
Baxter International Inc. |
Procedes pour determiner des substances actives dans des conjugues promedicament-peg-proteine avec des agents peg liberables (depegylation in vitro)
|
WO2010051335A1
(fr)
*
|
2008-10-31 |
2010-05-06 |
Amgen Inc. |
Matériels et procédés associés à la mobilisation de cellules souches par le facteur de croissance hématopoïétique g-csf polypégylé
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
WO2010077297A1
(fr)
|
2008-12-09 |
2010-07-08 |
Halozyme, Inc. |
Polypeptides ph20 solubles étendus et leurs applications
|
PL2356467T3
(pl)
|
2008-12-11 |
2013-12-31 |
Baxalta Inc |
Wykrywanie fizjologicznie dopuszczalnych cząsteczek polimeru z zastosowaniem spektroskopii w bliskiej podczerwieni
|
US8691205B2
(en)
|
2008-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corporation |
Mono- and di-PEG IL-10 production; and uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
JP2012525847A
(ja)
|
2009-05-05 |
2012-10-25 |
アムジエン・インコーポレーテツド |
Fgf21変異体およびその使用
|
PE20160718A1
(es)
|
2009-05-05 |
2016-08-03 |
Amgen Inc |
Polipeptidos mutantes fgf21
|
RU2573911C2
(ru)
|
2009-05-20 |
2016-01-27 |
Байомарин Фармасьютикал Инк. |
Варианты натрийуретического пептида с-типа
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
SG176922A1
(en)
|
2009-06-19 |
2012-01-30 |
Medimmune Llc |
Protease variants
|
JP2012531596A
(ja)
|
2009-06-25 |
2012-12-10 |
サヴィエント・ファーマシューティカルズ・インコーポレイテッド |
Peg化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
EA026112B1
(ru)
|
2009-09-17 |
2017-03-31 |
Бакстер Хелскэа, С.А. |
Стабильная композиция, содержащая гиалуронидазу и иммуноглобулин, и способы ее применения
|
CA2775287A1
(fr)
*
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Modification de polypeptide
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
EP2494073B1
(fr)
|
2009-10-26 |
2017-11-29 |
AGCT GmbH |
Conjugués de nucléotides et méthodes d'utilisation associées
|
AU2010313497B2
(en)
|
2009-10-30 |
2013-08-01 |
Boehringer Ingelheim International Gmbh |
Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
|
ES2632431T3
(es)
|
2009-10-30 |
2017-09-13 |
Ntf Therapeutics, Inc. |
Moléculas de neurturina mejoradas
|
US20140066370A1
(en)
|
2009-11-23 |
2014-03-06 |
Amylin Pharmaceuticals, Llc |
Polypeptide Conjugate
|
EP3778917A3
(fr)
|
2009-12-04 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Anticorps multispécifiques, analogues d'anticorps, compositions et procédés
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
SG181769A1
(en)
|
2009-12-21 |
2012-07-30 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
CN102753573A
(zh)
|
2009-12-21 |
2012-10-24 |
Ambrx公司 |
经过修饰的牛促生长素多肽和其用途
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
WO2011101242A1
(fr)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Molécules de facteur viii avec liaison réduite au vwf
|
MX2012010148A
(es)
|
2010-03-04 |
2013-01-22 |
Pfenex Inc |
Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
|
AU2011235210B2
(en)
|
2010-04-01 |
2015-07-16 |
Pfenex Inc. |
Methods for G-CSF production in a Pseudomonas host cell
|
US9517264B2
(en)
|
2010-04-15 |
2016-12-13 |
Amgen Inc. |
Human FGF receptor and β-Klotho binding proteins
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
US8961960B2
(en)
|
2010-04-27 |
2015-02-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
AU2011248489B2
(en)
|
2010-04-28 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
|
JP6008838B2
(ja)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
アスパラギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
EP2563383B1
(fr)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthétases
|
CN102234310B
(zh)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
一种聚乙二醇修饰蛋白的分离纯化方法
|
CA2797978C
(fr)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Decouverte innovante de compositions therapeutiques, diagnostiques et a base d'anticorps liees des fragments proteiques de methionyl-arnt-synthetases
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
JP5976638B2
(ja)
|
2010-05-03 |
2016-08-23 |
エータイアー ファーマ, インコーポレイテッド |
アルギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011140267A2
(fr)
|
2010-05-04 |
2011-11-10 |
Atyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
|
JP2013528374A
(ja)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Vla4のポリペプチド阻害剤
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
WO2011146410A2
(fr)
|
2010-05-17 |
2011-11-24 |
Atyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases
|
US8927488B2
(en)
|
2010-05-17 |
2015-01-06 |
Cebix, Inc. |
Pegylated C-peptide
|
WO2011150133A2
(fr)
|
2010-05-26 |
2011-12-01 |
Bristol-Myers Squibb Company |
Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
|
CN103096913B
(zh)
|
2010-05-27 |
2017-07-18 |
Atyr 医药公司 |
与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
EP2575857B1
(fr)
|
2010-06-01 |
2018-01-24 |
aTyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, diagnostiques, et d'anticorps associés à des fragments de protéine de lysyl-tarn synthétases
|
WO2011159930A2
(fr)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Systèmes d'amortissement permettant de stabiliser des médicaments dans des dispositifs de distribution de médicaments
|
EP2585065A1
(fr)
|
2010-06-24 |
2013-05-01 |
Panmed Ltd. |
Traitement de maladies associées au virus de l'hépatite c utilisant de l'hydroxychloroquine ou de l'hydroxychloroquine associée à un agent antiviral
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
CN102971006A
(zh)
|
2010-07-15 |
2013-03-13 |
诺沃—诺迪斯克有限公司 |
稳定的因子viii变体
|
DK2595624T3
(en)
|
2010-07-20 |
2018-03-26 |
Halozyme Inc |
Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
|
AR082319A1
(es)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
|
CA2807552A1
(fr)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Acides nucleiques modifies et leurs procedes d'utilisation
|
RU2446173C1
(ru)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
|
AU2011291943B2
(en)
|
2010-08-17 |
2015-01-22 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
EP3466968A1
(fr)
|
2010-09-15 |
2019-04-10 |
Stichting Sanquin Bloedvoorziening |
Variantes de facteur viii dotées d'un apport cellulaire réduit
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP3241558B1
(fr)
|
2010-09-28 |
2021-03-03 |
Aegerion Pharmaceuticals, Inc. |
Leptines hautement solubles
|
WO2012045704A1
(fr)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
Nouveaux traitements d'une infection par le virus de l'hépatite c
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
CN102453089B
(zh)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
CN103933577B
(zh)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
PT2643019T
(pt)
|
2010-11-24 |
2019-04-23 |
Lexicon Pharmaceuticals Inc |
Anticorpos para notum pectinacetilesterase
|
CN103221053A
(zh)
|
2010-11-30 |
2013-07-24 |
诺华有限公司 |
丙型肝炎病毒感染的新疗法
|
CN102485742A
(zh)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
JP5899241B2
(ja)
|
2010-12-21 |
2016-04-06 |
ネクター セラピューティクス |
ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012088422A1
(fr)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane
|
WO2012109387A1
(fr)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition et formulation lipidique d'une enzyme dégradant le hyaluronane et son utilisation pour le traitement de l'hyperplasie bénigne de la prostate
|
CN103930437A
(zh)
|
2011-03-16 |
2014-07-16 |
安姆根有限公司 |
Nav1.3和Nav1.7的强效及选择性抑制剂
|
AU2012236889A1
(en)
*
|
2011-03-25 |
2013-05-09 |
The Trustees Of Columbia University In The City Of New York |
Pegylated human HDL particle and process for production thereof
|
CN103476409A
(zh)
|
2011-03-31 |
2013-12-25 |
诺华股份有限公司 |
治疗丙肝病毒感染的阿拉泊韦
|
CA2831675A1
(fr)
|
2011-04-01 |
2012-10-04 |
Novartis Ag |
Traitement destine a une infection par le virus de l'hepatite b seul ou en combinaison avec le virus de l'hepatite delta et a des maladies hepatiques associees
|
AU2012241859A1
(en)
|
2011-04-13 |
2013-10-10 |
Debiopharm International Sa |
Treatment of Hepatitis C virus infection with alisporivir
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
SI2714735T1
(sl)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Protitelesa, specifična za TGF-beta
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
WO2012174480A2
(fr)
|
2011-06-17 |
2012-12-20 |
Halozyme, Inc. |
Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
EP2726502A1
(fr)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Polypeptides de fusion de relaxine et leurs utilisations
|
HUE029855T2
(en)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97 antibody conjugates
|
EP2729160B1
(fr)
|
2011-07-08 |
2019-03-27 |
Aegerion Pharmaceuticals, Inc. |
Polypeptides manipulés présentant une durée d'action accrue et une immunogénicité réduite
|
CN102952067A
(zh)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
|
MX2014002260A
(es)
|
2011-08-31 |
2014-08-18 |
Amgen Inc |
Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
|
WO2013040501A1
(fr)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
RU2014116988A
(ru)
|
2011-09-27 |
2015-11-10 |
Новартис Аг |
Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
|
RU2014114849A
(ru)
|
2011-10-14 |
2015-11-20 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
|
AU2012328880B2
(en)
|
2011-10-24 |
2017-02-23 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US9198829B2
(en)
|
2011-10-25 |
2015-12-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2013067029A2
(fr)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Domaines de liaison à la fibronectine à immunogénicité réduite
|
US8962553B2
(en)
|
2011-11-17 |
2015-02-24 |
Cebix Ab |
Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
|
WO2013101509A2
(fr)
|
2011-12-15 |
2013-07-04 |
Alternative Innovative Technologies Llc |
Conjugués de protéine de fusion hsp70 et leurs utilisations
|
MX361727B
(es)
|
2011-12-30 |
2018-12-14 |
Halozyme Inc |
Variantes de polipeptido ph20, formulaciones y usos de las mismas.
|
JP2015506369A
(ja)
|
2012-01-30 |
2015-03-02 |
アレコー リミテッド |
安定化された水性抗体組成物
|
IN2014MN01642A
(fr)
|
2012-02-16 |
2015-07-03 |
Atyr Pharma Inc |
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Xten共役組成物およびそれを製造する方法
|
EP2821079A4
(fr)
|
2012-02-29 |
2016-05-04 |
Toray Industries |
Suppresseur d'effusion de cavité corporelle
|
PL2822575T3
(pl)
|
2012-03-03 |
2020-08-10 |
Immungene, Inc. |
Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
EP2830663B1
(fr)
|
2012-03-30 |
2019-02-06 |
Sorrento Therapeutics Inc. |
Anticorps complètement humains qui se lient à vegfr2
|
WO2013151774A1
(fr)
|
2012-04-04 |
2013-10-10 |
Halozyme, Inc. |
Polythérapie par un agent anti-hyaluronane et un taxane ciblant une tumeur
|
EP3553086A1
(fr)
|
2012-05-31 |
2019-10-16 |
Sorrento Therapeutics Inc. |
Protéines de liaison à un antigène se liant à pd-l1
|
CN104583235B
(zh)
|
2012-06-08 |
2019-03-01 |
苏特罗生物制药公司 |
含位点特异非天然氨基酸残基的抗体、其制备和使用方法
|
EP2864358B1
(fr)
|
2012-06-22 |
2019-08-07 |
Sorrento Therapeutics, Inc. |
Protéines de liaison à un antigène qui se lient à ccr2
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014074218A1
(fr)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Composés et procédés pour produire un conjugué
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
CA2890906A1
(fr)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Ligature pictet-spengler pour la modification chimique de proteines
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
WO2014099984A1
(fr)
|
2012-12-20 |
2014-06-26 |
Amgen Inc. |
Agonistes du récepteur apj et leurs utilisations
|
CN103908660B
(zh)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
|
WO2014120891A2
(fr)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Protéines d'échafaudage à base de fibronectine
|
CN103113466B
(zh)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
聚乙二醇修饰的重组人干扰素β-1b及制备方法
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
ES2774549T3
(es)
|
2013-03-13 |
2020-07-21 |
Bioasis Technologies Inc |
Fragmentos de P97 y usos de los mismos
|
RU2535002C2
(ru)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
|
RU2679889C2
(ru)
|
2013-04-18 |
2019-02-14 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
EP3010527B1
(fr)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Méthode d'évaluation de l'identité et de la stabilité d'une protéine
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
WO2015031673A2
(fr)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Conjugués comportant des régions fc modifiées pour cibler le snc et méthodes pour les utiliser
|
EP3038642A4
(fr)
|
2013-08-30 |
2017-01-18 |
Armo Biosciences, Inc. |
Méthodes d'utilisation d'interleukine 10 dans le traitement de maladies et de troubles
|
BR112016005716A2
(pt)
|
2013-10-02 |
2017-09-12 |
Nat Institutes Of Health |
miméticos de fator de crescimento semelhante à insulina para uso em terapia
|
WO2015054658A1
(fr)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
|
WO2015057908A1
(fr)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Méthodes de traitement du diabete et de troubles associés
|
CA2928710A1
(fr)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
|
EP3068891A1
(fr)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Glycoprotéines modifiées et leurs utilisations
|
WO2015081282A1
(fr)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
|
UY35874A
(es)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
Un proceso para la preparación de una composición de proteínas pegiladas
|
WO2015130963A2
(fr)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions et méthodes d'administration au cerveau de protéine insuline ou insulinoïde
|
CN106573072A
(zh)
|
2014-06-02 |
2017-04-19 |
阿尔莫生物科技股份有限公司 |
降低血清胆固醇的方法
|
CA2951391C
(fr)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Polypeptides d'apeline
|
AU2015274482B2
(en)
|
2014-06-12 |
2018-11-08 |
Ra Pharmaceuticals, Inc. |
Modulation of complement activity
|
CA2958673A1
(fr)
|
2014-08-22 |
2016-02-25 |
Sorrento Therapeutics, Inc. |
Proteines de fixation antigenique fixant le cxcr3
|
DK3186281T3
(da)
|
2014-08-28 |
2019-06-11 |
Halozyme Inc |
Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
|
JP2017536098A
(ja)
|
2014-10-14 |
2017-12-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−15組成物及びその使用
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
EP3209320B1
(fr)
|
2014-10-22 |
2023-03-08 |
Armo Biosciences, Inc. |
Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
MX2017005244A
(es)
|
2014-11-06 |
2017-08-18 |
Pharmaessentia Corp |
Regimen de dosificacion para interferon pegilado.
|
US10046058B2
(en)
*
|
2014-12-02 |
2018-08-14 |
Rezolute, Inc. |
Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
|
CN104491843B
(zh)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG‑CSF活性药物组合物
|
HUE056613T2
(hu)
|
2015-01-28 |
2022-02-28 |
Ra Pharmaceuticals Inc |
Komplementaktivitás modulátorai
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
US10335492B2
(en)
*
|
2015-03-03 |
2019-07-02 |
Nansha Biologics (Hong Kong) Limited |
Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation
|
WO2016141111A1
(fr)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Traitement d'une hyperinsulinémie post-prandiale et d'une hypoglycémie après chirurgie bariatrique
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
US20180118799A1
(en)
|
2015-04-13 |
2018-05-03 |
National Institute Of Advanced Industrial Science And Technology |
Cyclized cytokine and method for producing same
|
EP4014985A1
(fr)
|
2015-05-01 |
2022-06-22 |
Allysta Pharmaceuticals, Inc. |
Peptidomimétiques de l'adiponectine pour le traitement de troubles oculaires
|
WO2016191587A1
(fr)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Interleukine 10 pégylée utilisée pour le traitement du cancer
|
WO2017024285A2
(fr)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Fragments d'anticorps contre le récepteur d'insuline et utilisations de ceux-ci pour traiter l'hypoglycémie
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
EP3351561A4
(fr)
*
|
2015-09-18 |
2019-05-15 |
University of Miyazaki |
Dérivé d'adrénomédulline à action prolongée
|
CA3000697A1
(fr)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Traitement de troubles lies a l'acide biliaire
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
KR20180088459A
(ko)
|
2015-12-08 |
2018-08-03 |
바이오마린 파머수티컬 인크. |
골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도
|
HUE061759T2
(hu)
|
2015-12-16 |
2023-08-28 |
Ra Pharmaceuticals Inc |
Komplement aktivitás modulátorai
|
CN116333124A
(zh)
|
2016-01-29 |
2023-06-27 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
BR112019005944A2
(pt)
|
2016-09-28 |
2019-06-11 |
Musc Foudation For Res Development |
anticorpos que se ligam à interleucina 2 e usos dos mesmos
|
CA3045114A1
(fr)
|
2016-12-07 |
2018-06-14 |
Ra Pharmaceuticals, Inc. |
Modulateurs de l'activite du complement
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
MY193457A
(en)
|
2017-02-08 |
2022-10-14 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
SG11201912071QA
(en)
|
2017-06-22 |
2020-01-30 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
KR102020995B1
(ko)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
|
EP3732254A4
(fr)
|
2017-12-26 |
2021-12-22 |
Becton, Dickinson and Company |
Colorants polymères, solvatés à l'eau, excitables aux ultraviolets profonds
|
JP2021509805A
(ja)
|
2017-12-27 |
2021-04-08 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
顆粒球コロニー刺激因子活性を示すポリペプチド
|
CN112135837A
(zh)
*
|
2018-03-14 |
2020-12-25 |
勇·巴 |
聚乙二醇化抗冻蛋白及其制备和使用方法
|
JP2021519841A
(ja)
|
2018-03-30 |
2021-08-12 |
ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company |
ペンダントクロモフォアを有する水溶性ポリマー色素
|
CA3097968A1
(fr)
|
2018-04-24 |
2019-10-31 |
Andrew Phillip SPASOFF |
Procede de fabrication de compositions pharmaceutiques injectables
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
US20220162336A1
(en)
|
2018-07-22 |
2022-05-26 |
Bioasis Technologies, Inc. |
Treatment of lymphatic metastases
|
CN116948006A
(zh)
|
2018-09-11 |
2023-10-27 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其用途
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
MX2021007843A
(es)
|
2018-12-28 |
2021-08-11 |
Vertex Pharma |
Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
EP3955965A1
(fr)
*
|
2019-04-15 |
2022-02-23 |
NOF Corporation |
Conjugué de substance biologique et de polymère séquencé et dérivé de polymère séquencé pour obtenir ledit conjugué
|
AU2020258384A1
(en)
|
2019-04-15 |
2021-11-04 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
US20230204597A1
(en)
|
2020-03-20 |
2023-06-29 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
US11602598B1
(en)
*
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
CN112710826A
(zh)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
一种提高试剂稳定性的包被和封闭方法
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
CN113214328B
(zh)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
一种双水相体系以及基于双水相体系的单糖分离方法
|
EP4155349A1
(fr)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Colorants absorbants jaunes verts solubles dans l'eau
|
WO2024007016A2
(fr)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Nouveaux colorants fluorescents et polymères issus de dérivés de dihydrophenanthrène
|
WO2024044327A1
(fr)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Monomères dhnt et colorants polymères ayant des propriétés photophysiques modifiées
|